What Happened?
Shares of digital medical services platform Teladoc Health (NYSE: TDOC) jumped 6.3% in the morning session after the company reported third-quarter financial results that surpassed Wall Street's revenue expectations, even as other key metrics declined compared to the previous year.
Teladoc posted revenue of $626.4 million, which represented a 2.2% year-over-year decline but came in slightly ahead of analyst forecasts. The company's adjusted EBITDA of $66.07 million also topped estimates. However, the company's GAAP loss of $0.28 per share was wider than Wall Street had anticipated. The stock's positive reaction suggests investors focused on the revenue and EBITDA beats, viewing the results as better than feared. Adding to this sentiment, Teladoc's revenue guidance for the next quarter was roughly in line with expectations, reassuring investors about the near-term outlook.
Is now the time to buy Teladoc? Access our full analysis report here.
What Is The Market Telling Us
Teladoc’s shares are extremely volatile and have had 47 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 6 days ago when the stock gained 9.9% on the news that the release of a cooler-than-expected inflation report fueled optimism for a potential interest rate cut from the Federal Reserve. The September Consumer Price Index (CPI) indicated a 3.0% year-over-year rise, slightly below the 3.1% forecast. Investors viewed this as a positive sign that inflation is moderating, increasing the probability of a more accommodative monetary policy from the central bank. A potential rate cut is seen as a significant catalyst for the tech sector, as lower borrowing costs can enhance profitability and encourage companies to reinvest in growth and innovation. This renewed confidence was reflected in the market's broad gains, with technology and semiconductor stocks leading the charge.
Teladoc is down 8.2% since the beginning of the year, and at $8.74 per share, it is trading 39% below its 52-week high of $14.33 from February 2025. Investors who bought $1,000 worth of Teladoc’s shares 5 years ago would now be looking at an investment worth $44.50.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.
